Back to top
more

STERIS (STE)

(Delayed Data from NYSE)

$236.01 USD

236.01
258,460

+1.87 (0.80%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $236.04 +0.03 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Don't Overlook Steris (STE) International Revenue Trends While Assessing the Stock

Review Steris' (STE) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

STERIS (STE) Q1 Earnings Beat Estimates, Operating Margin Falls

STERIS' (STE) first-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The contraction of the operating margin is concerning.

Steris (STE) Reports Q1 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Steris (STE) Beats Q1 Earnings and Revenue Estimates

Steris (STE) delivered earnings and revenue surprises of 1% and 1.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Tops Revenue Estimates

Tandem Diabetes Care (TNDM) delivered earnings and revenue surprises of 12.96% and 7.50%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

What Analyst Projections for Key Metrics Reveal About Steris (STE) Q1 Earnings

Get a deeper insight into the potential performance of Steris (STE) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Here's How STERIS (STE) is Placed Ahead of Q1 Earnings

STERIS' (STE) first-quarter fiscal 2025 results are likely to reflect the positives of the normalization of the Healthcare backlog, along with a core focus on pharma and MedTech.

STERIS (STE) AST Business Expands, New Offerings Aid Growth

STERIS' (STE) AST successfully offers an extensive range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.

Should You Hold STERIS (STE) Stock Now? Here's What to Consider

STERIS' (STE) Healthcare business and strong rebound prospects of the AST segment appear encouraging. However, macroeconomic concerns remain a challenge.

STERIS (STE) Gains From New Offerings, Macro Issues Ail

STERIS' (STE) AST successfully offers a wide range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.

Steris (STE) Up 2% Since Last Earnings Report: Can It Continue?

Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Unlocking Steris (STE) International Revenues: Trends, Surprises, and Prospects

Explore how Steris' (STE) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

STERIS (STE) Q4 Earnings Match Estimates, Margins Contract

STERIS' (STE) fourth-quarter performance in AST is dented by a decline in capital equipment revenues. The contraction of margins is concerning.

Steris (STE) Reports Q4 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Steris (STE) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Steris (STE) Matches Q4 Earnings Estimates

Steris (STE) delivered earnings and revenue surprises of 0% and 3.07%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Shockwave Medical (SWAV) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Shockwave Medical (SWAV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exploring Analyst Estimates for Steris (STE) Q4 Earnings, Beyond Revenue and EPS

Get a deeper insight into the potential performance of Steris (STE) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

The Zacks Analyst Blog Highlights Micron Technology, Anheuser-Busch, Duke Energy, ON Semiconductor and STERIS

Micron Technology, Anheuser-Busch, Duke Energy, ON Semiconductor and STERIS are included in this Analyst Blog.

Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Tops Revenue Estimates

Sight Sciences (SGHT) delivered earnings and revenue surprises of -13.79% and 5.06%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Sheraz Mian headshot

Top Stock Reports for Micron Technology, Anheuser-Busch & Duke Energy

Today's Research Daily features new research reports on 16 major stocks, including Micron Technology, Inc. (MU), Anheuser-Busch InBev SA/NV (BUD) and Duke Energy Corporation (DUK).

Here's Why You Should Retain STERIS (STE) Stock for Now

STERIS' (STE) strong prospects in the healthcare and pharmaceutical industries bode well for investors.

Should You Buy STERIS (STE) Stock Ahead of Q4 Earnings?

STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.

Zacks Industry Outlook Highlights Edwards Lifesciences, DexCom and STERIS

Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.

Here's Why Steris (STE) is Poised for a Turnaround After Losing -9.06% in 4 Weeks

The heavy selling pressure might have exhausted for Steris (STE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.